Ocular Therapeutix: $23.8m in new funding will help advance eye therapies

Ocular Therapeutix Inc., a Bedford company looking to use is proprietary hydrogel technology to commercialize treatments for eye ailments, said Monday that it recently closed a Series D extension round of financing totaling $23.8 million.

All existing institutional investors, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures participated in the round, Ocular Therapeutix said in a press release.


The company said it has raised about $65 million to date.

Ocular Therapeutix plans to use the funding to advance drug candidates in its pipeline.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

They include travoprost, which is designed to treat glaucoma, and dexamethasone, which looks to relieve post-operative inflammation and pain.

The funds will also be used to develop sustained release therapies for retinal diseases in collaboration with pharma partners, Ocular Therapeutix said.

Another product the company is working on is called ReSure Sealant, which would be used to seal clear corneal incisions following lens implantation surgery.

Chris Reidy can be reached at
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of